-+ 0.00%
-+ 0.00%
-+ 0.00%

Canaccord Genuity Maintains Buy on Travere Therapeutics, Raises Price Target to $72

Benzinga·11/04/2026 23:47:55
Listen to the news
Canaccord Genuity analyst Edward Nash maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and raises the price target from $70 to $72.